Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radioimmunotherapy, Radiation, and Chemotherapy for Standard-Risk Medulloblastoma
NCT00058370Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2003
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iodine I 131 monoclonal antibody 3F8 in medulloblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2003; status: completed.
02
Drugs
iodine I 131 monoclonal antibody 3F8
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT00058370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058370.